Penumbra (PEN) Total Current Liabilities (2014 - 2026)
Penumbra's (PEN) quarterly Total Current Liabilities came in at $211.7 million in Q1 2026, up 33.47% year-on-year from $158.6 million in Q1 2025, and up 15.62% on a QoQ basis from $183.1 million in Q4 2025.
Penumbra (PEN) Total Current Liabilities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Total Current Liabilities data on file, last reported at $211.7 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 33.47% year-over-year to $211.7 million in Q1 2026; TTM through Mar 2026 was $211.7 million, a 33.47% increase from a year earlier, with the FY2025 full-year figure at $183.1 million, up 15.65% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $211.7 million, up from $183.1 million in the prior quarter.
- Over the last five years, Total Current Liabilities for PEN reached as high as $211.7 million in Q1 2026 and fell as low as $130.1 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $155.4 million across 5 years, with a median of $151.1 million in 2023.
- Across the five-year window, Total Current Liabilities fell 1.02% in 2023 and surged 33.47% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $144.9 million in 2022, then climbed by 4.29% to $151.1 million in 2023, then grew by 4.76% to $158.3 million in 2024, then climbed by 15.65% to $183.1 million in 2025, then climbed by 15.62% to $211.7 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $211.7 million in Q1 2026, $183.1 million in Q4 2025, and $169.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 18.38 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.32 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 11.66 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 4.57 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 1.41 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2.22 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.70 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.53 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 1.60 Bn |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 211.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 211.73 Mn |
| Dec 31, 2025 | 183.13 Mn |
| Sep 30, 2025 | 169.60 Mn |
| Jun 30, 2025 | 157.76 Mn |
| Mar 31, 2025 | 158.63 Mn |
| Dec 31, 2024 | 158.35 Mn |
| Sep 30, 2024 | 153.19 Mn |
| Jun 30, 2024 | 150.99 Mn |
| Mar 31, 2024 | 152.80 Mn |
| Dec 31, 2023 | 151.14 Mn |
| Sep 30, 2023 | 145.08 Mn |
| Jun 30, 2023 | 144.12 Mn |
| Mar 31, 2023 | 146.33 Mn |
| Dec 31, 2022 | 144.93 Mn |
| Sep 30, 2022 | 138.33 Mn |
| Jun 30, 2022 | 145.60 Mn |
| Mar 31, 2022 | 130.10 Mn |
| Dec 31, 2021 | 123.20 Mn |
| Sep 30, 2021 | 116.06 Mn |
| Mar 31, 2021 | 111.86 Mn |